Centessa Pharmaceuticals (NASDAQ:CNTA) Given Peer Perform Rating at Wolfe Research

Centessa Pharmaceuticals (NASDAQ:CNTA)‘s stock had its “peer perform” rating restated by stock analysts at Wolfe Research in a report issued on Tuesday,Benzinga reports.

Other research analysts also recently issued reports about the company. Oppenheimer increased their target price on Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Piper Sandler reaffirmed an “overweight” rating on shares of Centessa Pharmaceuticals in a research note on Friday, January 16th. Truist Financial increased their price objective on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. TD Cowen reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Finally, B. Riley Financial boosted their target price on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, December 1st. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $40.00.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock traded up $12.36 during midday trading on Tuesday, reaching $39.94. 25,443,749 shares of the stock traded hands, compared to its average volume of 1,818,023. The stock has a market cap of $5.83 billion, a P/E ratio of -21.84 and a beta of 1.54. The stock’s fifty day moving average is $25.96 and its 200-day moving average is $25.12. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 12 month low of $9.60 and a 12 month high of $40.26.

Insider Activity

In related news, insider Gregory M. Weinhoff sold 73,196 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the sale, the insider owned 65,925 shares in the company, valued at approximately $1,735,805.25. This represents a 52.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Iqbal J. Hussain sold 38,951 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the sale, the insider owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 349,073 shares of company stock valued at $9,429,412. 7.09% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. TD Waterhouse Canada Inc. bought a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd bought a new stake in Centessa Pharmaceuticals in the fourth quarter worth about $36,000. T. Rowe Price Investment Management Inc. boosted its position in shares of Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after buying an additional 1,516 shares during the period. Wells Fargo & Company MN boosted its position in shares of Centessa Pharmaceuticals by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after buying an additional 1,008 shares during the period. Finally, Knott David M Jr bought a new position in shares of Centessa Pharmaceuticals during the fourth quarter valued at approximately $100,000. Institutional investors own 82.01% of the company’s stock.

Trending Headlines about Centessa Pharmaceuticals

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to buy Centessa in a multi‑billion dollar deal that values the company at an initial ~$6.3 billion with potential to rise (reports cite up to $7.8B including milestones). The acquisition validates Centessa’s sleep‑wake OX2R agonist program and is the primary driver of the share rise. Read More. Read More.
• Positive Sentiment: Centessa’s pipeline and strategic fit: Lilly emphasized Centessa’s OX2R agonists as potentially best‑in‑class candidates to treat excessive daytime sleepiness and narcolepsy, which supports premium pricing for the deal and long‑term value for shareholders. Read More.
• Positive Sentiment: Unusual options activity: Large call buying was reported (nearly a 5x jump vs. typical call volume), consistent with bullish positioning tied to the takeover news and expectations of an offer-related premium. (Entry: unusual options trading reported 3/31)
• Neutral Sentiment: Analyst stance: Needham reaffirmed a “hold” on the stock — a sign analysts are waiting for deal closing and final terms rather than changing near‑term views immediately. Read More.
• Neutral Sentiment: Trading mechanics: Volume surged well above average and the stock is trading far above its 50‑ and 200‑day moving averages, reflecting deal news and momentum rather than company operational updates. (Background trading data)
• Negative Sentiment: Potential shareholder challenge / fairness probe: Halper Sadeh LLC is investigating whether Centessa’s shareholders are receiving a fair price, which could lead to legal scrutiny or demands for a higher bid and introduce execution risk or delay. Read More.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.